IQVIA (IQV) – Research Analysts’ Weekly Ratings Changes

IQVIA (NYSE: IQV) recently received a number of ratings updates from brokerages and research firms:

• 8/1/2026 – IQVIA was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/29/2026 – IQVIA had its price target raised by Royal Bank Of Canada from $221.00 to $247.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by TD Cowen from $233.00 to $288.00. They now have a “buy” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by BMO Capital Markets from $210.00 to $270.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by Stifel Nicolaus from $220.00 to $276.00. They now have a “buy” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by JPMorgan Chase & Co. from $225.00 to $285.00. They now have an “overweight” rating on the stock.
• 7/29/2026 – IQVIA had its price target raised by Robert W. Baird from $252.00 to $287.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – IQVIA had its “overweight” rating reaffirmed by Barclays PLC.
• 7/28/2026 – IQVIA was upgraded by William Blair to “strong-buy”.
• 7/15/2026 – IQVIA was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 7/13/2026 – IQVIA had its price target raised by Mizuho from $215.00 to $230.00. They now have an “outperform” rating on the stock.
• 7/9/2026 – IQVIA was given a new $240.00 price target by Deutsche Bank Aktiengesellschaft.
• 7/6/2026 – IQVIA had its “buy” rating reaffirmed by HSBC Holdings plc. They now have a $240.00 price target on the stock.
• 7/1/2026 – IQVIA had its price target raised by Robert W. Baird from $230.00 to $249.00. They now have an “outperform” rating on the stock.
• 6/27/2026 – IQVIA was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. The trade was a 15.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by company insiders.

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.